New York, Feb 13, 2026, 19:34 EST — After-hours
ImmunityBio Inc dropped 10.2% Friday, finishing at $5.95 after swinging between $7.30 and $5.94 during the session. About 39.2 million shares traded hands. In after-hours moves, the stock recovered slightly, up 2.6% to $6.10. (StockAnalysis)
A late-week dip refocuses traders on ImmunityBio’s upcoming catalysts. The stock took off in January after the company reported preliminary 2025 net product revenue around $113 million and wrapped up the year sitting on roughly $242.8 million in cash and marketable securities. “We delivered strong quarter-over-quarter revenue growth,” CEO Richard Adcock said at the time. (ImmunityBio)
Just days later, ImmunityBio disclosed that U.S. regulators want more information backing a possible resubmission of its supplemental biologics license application, or sBLA, for Anktiva—aimed at early-stage bladder cancer. The company plans to send in the materials the FDA requested within 30 days. No new clinical trials are part of this package, ImmunityBio said. (ImmunityBio)
The Pomerantz Law Firm put out a notice Thursday, saying it’s looking into claims for ImmunityBio investors after a January announcement from the company sent the stock tumbling that day. (PR Newswire)
On the SEC filings front, a flurry of Form 4s hit: Adcock disclosed that 140,048 shares were withheld at $6.93 to cover taxes from stock awards vesting Feb. 10. Executive chairman Patrick Soon-Shiong logged 118,560 shares withheld at that same price. The chief accounting officer’s report showed a smaller number of shares, also for tax withholding on vested stock. (SEC)
Tax-withholding sales happen regularly, but when it comes to a stock that can jump or drop by double digits in a day, they tend to hit especially hard.
Anktiva picked up U.S. approval in April 2024 for use with BCG—the old tuberculosis vaccine that doubles as a go-to bladder cancer therapy. Executive chairman Soon-Shiong told Reuters the goal is “generate cancer-free long-term overall survival,” but he also acknowledged Merck’s Keytruda is already part of the landscape. (Reuters)
Other major names are wading into the BCG field too. Pfizer’s late-stage sasanlimab-plus-BCG results caught Guggenheim’s Vamil Divan’s attention—he called it “a noteworthy development in a treatment space historically dominated by BCG monotherapy.” (Reuters)
Regulatory hurdles have dogged ImmunityBio. Back in 2023, the FDA refused to greenlight the company’s bladder-cancer therapy, pointing to shortcomings discovered during pre-license checks of contract manufacturers and demanding additional data and a fresh safety update in any resubmission. (Reuters)
Friday’s drop has traders sifting through filings, notices, and shifting positions, looking for anything that might actually move the needle on the Anktiva timetable or alter the sales path.
With U.S. stock markets shuttered Monday for Presidents’ Day, traders will look to Tuesday’s opening bell for clues on whether Friday’s slide was a simple pre-holiday pullback or something more. (NASDAQ Trader)
Eyes are turning to late February as ImmunityBio prepares for its slot at the ASCO Genitourinary Cancers Symposium, set for Feb. 26-28. According to Investing.com, the company’s next earnings report is expected on March 3. (ImmunityBio)
